{
    "clinical_study": {
        "@rank": "112492", 
        "acronym": "DIVA", 
        "arm_group": [
            {
                "arm_group_label": "Secnidazol-Ciprofloxacin", 
                "arm_group_type": "Experimental", 
                "description": "2g(single dose) of Secnidazol associated with 1g(2 doses of 500mg)of Ciprofloxacin during 3 days"
            }, 
            {
                "arm_group_label": "Amoxicillin-Clavulanic Acid", 
                "arm_group_type": "Active Comparator", 
                "description": "3g (3 doses of 1g) of Amoxicillin-Clavulanic acid during 10 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary outcome measure is to compare efficacy of an association of\n      Secnidazol(2g)-Ciprofloxacin(1g) (during 3 days) versus 3g of Amoxicillin-Clavulanic Acid\n      during 10 days for the Treatment of Uncomplicated Episode of Diverticular Sigmo\u00efditis Among\n      Adults in clinical and biological cure.\n\n      The cure rate will be evaluated at the second visit (14 days after the inclusion visit)"
        }, 
        "brief_title": "A Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmo\u00efditis Among Adults", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Diverticular Sigmo\u00efditis", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult\n\n          -  Recovering of written and dated informed consent form\n\n          -  Social Security medical cover\n\n          -  Left Iliac Fossa (LIF) pain\n\n          -  Moderate fever (>37.8\u00b0C)\n\n          -  Sensitivity/defence during LIF palpation\n\n        Biological results :\n\n          -  CRP > 10mg/L\n\n          -  NFS > 10G/L\n\n          -  Neutrophil Granulocytosis > 75%\n\n          -  Radiological results - presence to the scan :diverticul & pericolic infiltration\n\n        Exclusion Criteria:\n\n          -  Patients treated by antibiotherapy in the last 15 days prior inclusion\n\n          -  Patients treated by morphinic drug\n\n          -  Patients treated by anticoagulant drug\n\n          -  Pregnant or breast-feeding women\n\n          -  Patients presenting allergy to active principal, to galactose\n\n          -  Patients having taking part in another study in the last 3 months prior inclusion\n\n          -  Patients unable to comply with the study requirements\n\n          -  Patients presenting Chronic affection inconsistent with the study\n\n          -  Patients presenting high fever\n\n          -  Patients presenting abdominal contracture\n\n          -  Patients presenting immunosuppression\n\n          -  Radiological sign of complication (abscess>3cm)\n\n          -  Patients presenting Pathology inconsistent with efficacy evaluatio"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT01136434", 
            "nct_id": "NCT01733966", 
            "org_study_id": "IPR_SIGMO_09"
        }, 
        "intervention": [
            {
                "arm_group_label": "Secnidazol-Ciprofloxacin", 
                "description": "2g of microgranules of secnidazole. a single dose per day during 3 days.\n1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)", 
                "intervention_name": "Secnidazole, ciprofloxacine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Amoxicillin-Clavulanic Acid", 
                "description": "3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)", 
                "intervention_name": "Amoxicillin-Clavulanic Acid", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amoxicillin", 
                "Clavulanic Acids", 
                "Clavulanic Acid", 
                "Amoxicillin-Potassium Clavulanate Combination", 
                "Secnidazole", 
                "Ciprofloxacin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 21, 2012", 
        "number_of_arms": "2", 
        "official_title": "A Third Phase, Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmo\u00efditis Among Adults", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "France : AFSSAPS. (Agence Francaise de S\u00e9curit\u00e9 Sanitaire des Produits de Sant\u00e9).", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "to compare efficacy of an association of Secnidazol(2g)-Ciprofloxacin(1g) (during 3 days) versus 3g of Amoxicillin-Clavulanic Acid during 10 days for clinical and biological cure", 
            "safety_issue": "Yes", 
            "time_frame": "the cure rate will be evaluated at the second visit (14 days after the inclusion visit)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733966"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Quanta Medical", 
        "sponsors": {
            "collaborator": {
                "agency": "Laboratoires Iprad-Vegebom", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Quanta Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2010", 
        "why_stopped": "difficulties to recruit patients who suffer from this pathology"
    }
}